The potential of trace amines and their receptors for treating neurological and psychiatric diseases

Reviews on Recent Clinical Trials

Volumn 2, Issue 1, 2007, Pages 3-19

  Berry, M D ^a  

^a BRANDON UNIVERSITY   (Canada)

Author keywords

Affective disorders; Attention deficit hyperactivity disorders; Drug abuse dependence; Migraine; Schizophrenia; Trace amines

Indexed keywords

4 AMINOBUTYRIC ACID; 4 HYDROXYBUTYRIC ACID; ACETYLCHOLINE; AMINO ACID DECARBOXYLASE; AMPHETAMINE; ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE; DIAZEPAM; DOPAMINE; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; IMIPRAMINE; METHYLPHENIDATE; MODAFINIL; MONOAMINE DERIVATIVE; MONOAMINE OXIDASE INHIBITOR; N,N DIMETHYLTRYPTAMINE; NEUROLEPTIC AGENT; NORADRENALIN; OCTOPAMINE; OXEDRINE; PHENETHYLAMINE; PHENYLALANINE; PSYCHOTROPIC AGENT; RESERPINE; TRACE AMINE; TRACE AMINE ASSOCIATED RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT; TYRAMINE; TYROSINE; UNCLASSIFIED DRUG;

ALCOHOLISM; ANOREXIA; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; CHROMOSOME 6Q; CHROMOSOME 7P; CLUSTER HEADACHE; DEPRESSION; DIET RESTRICTION; DRUG ABUSE; DRUG DEPENDENCE; EATING DISORDER; ELECTROCONVULSIVE THERAPY; EPILEPSY; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERAMMONEMIA; MENTAL DISEASE; MIGRAINE; MONOTHERAPY; MOOD DISORDER; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW; REYE SYNDROME; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; STRESS; TOBACCO DEPENDENCE; URINARY EXCRETION;

EID: 34248173567     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488707779318107     Document Type: Review

References (197)

1. Borowsky B, Adham N, Jones KA, et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 2001; 98: 8966-71.
2. Bunzow JR, Sonders MS, Arttamangkul S, et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide: and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 2001; 60: 1181-8.
3. Berry MD. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 2004; 90: 257-71.
4. Lewin AH. Receptors of mammalian trace amines. AAPS J 2006; 8: E138-45.
5. Lindemann L, Hoener MC. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 2005; 26: 274-81.
6. Branchek TA, Blackburn TP. Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr Opin Pharmacol 2003; 3: 90-97.
7. Navarro HA, Gilmour BP, Lewin AH. A rapid functional assay for the human trace amine - associated receptor 1 based on the mobilization of internal calcium. J Biomol Screen 2006; e-pub July 10: doi:10.1177/ 1087057106289891 Accessed August 10, 2006.
8. Liberles SD, Buck LB. A second class of chemosensory receptors in the olfactory epithelium. Nature 2006; 442: 645-50.
9. Scanlan TS, Suchland KL, Hart ME, et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 2004; 10: 638-42.
10. Holt A. Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs? J Psychiatry Neurosci 2003; 28: 409-14.
11. Lindemann L, Ebeling M, Kratochwil NA, et al. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 2005; 85: 372-85.
12. Paterson IA, Juorio AV, Boulton AA. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 1990; 55: 1827-37.
13. Berry MD, Juorio AV, Li XM, Boulton AA. Aromatic L-amino acid decarboxylase: a neglected and misunderstood enzyme. Neurochem Res 1996; 21: 1075-87.
14. Bowsher RR, Henry DP. Aromatic L-amino decarboxylase. In: Boulton AA, Baker GB, Yu PH, Ed, Neuromethods: Neurotransmitter Enzymes. Clifton, New Jersey, Humana Press, Inc. 1986; 33-78.
15. Yang HY, Neff NH. The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 1974; 189: 733-40.
16. Berry MD, Juorio AV, Paterson IA. The functional role of monoamine oxidases A and B in the mammalian central nervous system. Prog Neurobiol 1994; 42: 375-91.
17. Holt A, Todd KG, Baker GB. The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain. Ann N Y Acad Sci 2003; 1009: 309-22.
18. Davis BA. Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects. J Chromatogr 1989; 466: 89-218.
19. Davis BA, Boulton AA. The trace amines and their acidic metabolites in depression - an overview. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 17-45.
20. McQuade PS. Analysis and the effects of some drugs on the metabolism of phenylethylamine and phenylacetic acid. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 607-14.
21. Huebert ND, Dulery BD, Schoun J, et al. Kinetics and metabolism of p-tyramine during monoamine oxidase inhibition by mofegiline. Clin Pharmacol Ther 1994; 56: 537-42.
22. Berretta N, Giustizieri M, Bernardi G, Mercuri NB. Trace amines reduce GABA(B) receptor-mediated presynaptic inhibition at GABAergic synapses of the rat substantia nigra pars compacta. Brain Res 2005; 1062: 175-8.
23. Fuxe K, Grobecker H, Jonsson J. The effect of β-phenylethylamine on central and peripheral monoamine-containing neurons. Eur J Pharmacol 1967; 2: 202-7.
24. Raiteri M, Del Carmine R, Bertollini A, Levi G. Effect of sympathomimetic amines on the synaptosomal transport of noradrenaline, dopamine and 5-hydroxytryptamine. Eur J Pharmacol 1977; 41: 133-43.
25. Parker EM, Cubeddu LX. Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J Pharmacol Exp Ther 1988; 245: 199-210.
26. Janssen PA, Leysen JE, Megens AA, Awouters FH. Does phenylethylamine act as an endogenous amphetamine in some patients? Int J Neuropsychopharmcol 1999; 2: 229-240.
27. Borison RL, Mosnaim AD, Sabelli HC. Brain 2-phenylethylamine as a major mediator for the central actions of amphetamine and methylphenidate. Life Sci 1975; 17: 1331-43.
28. Roeder T. Octopamine in invertebrates. Prog Neurobiol 1999; 59: 533-61.
29. Roeder T. Tyramine and octopamine: ruling behavior and metabolism. Annu Rev Entomol 2005; 50: 447-77.
30. Gloriam DE, Bjarnadottir TK, Schioth HB, Fredriksson R. High species variation within the repertoire of trace amine receptors. Ann N Y Acad Sci 2005; 1040: 323-7.
31. Hart ME, Suchland KL, Miyakawa M, et al. Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. J Med Chem 2006; 49: 1101-12.
32. Hiroi Y, Kim HH, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 2006; 103: 14104.
33. Knoll J. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2- yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. CNS Drug Rev 2001; 7: 317-45.
34. Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br J Pharmacol 1999; 128: 1723-32.
35. Ling L, Urichuk LJ, Sloley BD, et al. Synthesis of N-propargylphenelzine and analogues as neuroprotective agents. Bioorg Med Chem Lett 2001; 11: 2715-7.
36. Henry DP, Russell WL, Clemens J, Plebus LA. Phenylethylamine and p-tyramine in the extracellular space of the rat brain: quantification using a new radioenzymatic assay and in situ microdialysis. In: Boulton AA, Juorio AV, Downer RG, Ed, Trace Amines: Comparative and Clinical Neurobiology. Clifton, New Jersey, Humana Press, Inc. 1988; 239-250.
37. Durden DA, Davis BA. Determination of regional distributions of phenylethylamine and meta- and para-tyramine in rat brain regions and presence in human and dog plasma by an ultra-sensitive negative chemical ion gas chromatography-mass spectrometric (NCI-GC-MS) method. Neurochem Res 1993; 18: 995-1002.
38. Davis BA, Durden DA. Quantitative high resolution mass spectrometry of biogenic amines. In: Baker GB, Coutts RT, Ed, Analysis of biogenic amines, Part A: Evaluation of analytical methods in biological systems. Amsterdam, Elsevier. 1982; 129-149.
39. Durden DA, Boulton AA. Mass spectrometric analysis of some neurotransmitters and their precursors and metabolites. In: Lajtha A, Ed, Handbook of neurochemistry, Vol 2. New York, Plenum press. 1982; 103-132.
40. Kahler SG, Fahey MC. Metabolic disorders and mental retardation. Am J Med Genet C Semin Med Genet 2003; 117: 31-41.
41. Reynolds GP, Seakins JW, Gray DO. The urinary excretion of 2-phenylethylamine in phenylketonuria. Clin Chim Acta 1978; 83: 33-9.
42. Wolf ME, Mosnaim AD. Phenylethylamine in neuropsychiatric disorders. Gen Pharmacol 1983; 14: 385-90.
43. Premont RT, Gainetdinov RR, Caron MG. Following the trace of elusive amines. Proc Nad Acad Sci USA 2001; 98: 9474-5.
44. Reynolds GP. Phenylethylamine - a role in mental illness. Trends Neurosci 1979; 2: 265.
45. Olson MV, Varki A. Sequencing the chimpanzee genome: insights into human evolution and disease. Nat Rev Genet 2003; 4: 20-8.
46. Moja EA, Stoff DM, Gillin JC, Wyatt RJ. Dose-response effects of beta-phenylethylamine on stereotyped behavior in pargyline-pretreated rats. Biol Psychiatry 1976; 11: 731-42.
47. Dourish CT. An observational analysis of the behavioural effects of β - phenylethylamine in isolated and grouped mice. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 143-58.
48. Greenshaw AJ, Juorio AV, Boulton AA. Behavioral and neurochemical effects of deprenyl and β-phenylethylamine in Wistar rats. Brain Res Bull 1985; 15: 183-9.
49. Sandler M, Reynolds GP. Does phenylethylamine cause schizophrenia? Lancet 1976; 1: 70-1.
50. Greenshaw AJ. β-Phenylethylamine and reinforcement. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8: 615-20.
51. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063-72.
52. O'Reilly RL, Davis BA. Phenylethylamine and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18: 63-75.
53. Potkin SG, Karoum F, Chuang LW, et al. Phenylethylamine in paranoid chronic schizophrenia. Science 1979; 206: 470-1.
54. Potkin SG, Wyatt RJ, Karoum F. Phenylethylamine (PEA) and phenylacetic acid (PAA) in the urine of chronic schizophrenic patients and controls. Psychopharmacol Bull 1980; 16: 52-4.
55. O'Reilly R, Davis BA, Durden DA, et al. Plasma phenylethylamine in schizophrenic patients. Biol Psychiatry 1991; 30: 145-50.
56. Shirkande S, O'Reilly R, Davis B, Durden D, Malcolm D. Plasma phenylethylamine levels of schizophrenic patients. Can J Psychiatry 1995; 40: 221.
57. Gilka L. Schizophrenia, a disorder of tryptophan metabolism. Acta Psychiatr Scand Suppl 1975; 258: 1-83.
58. Anderson GM, Gerner RH, Cohen DJ, Fairbanks L. Central tryptamine turnover in depression, schizophrenia, and anorexia: measurement of indoleacetic acid in cerebrospinal fluid. Biol Psychiatry 1984; 19: 1427-35.
59. Jacob MS, Presti DE. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Med Hypotheses 2005; 64: 930-7.
60. Murray RM, Oon MC, Rodnight R, Birley JL, Smith A. Increased excretion of dimethyltryptamine and certain features of psychosis: a possible association. Arch Gen Psychiatry 1979; 36: 644-9.
61. Checkley SA, Murray RM, Oon MC, Rodnight R, Birley JL. A longitudinal study of urinary excretion of N,N,-dimethyltryptamine in psychotic patients. Br J Psychiatry 1980; 137: 236-9.
62. Tanimukai H, Ginther R, Spaide J, Bueno JR, Himwich HE. Detection of psychotomimetic N,N-dimethylated indoleamines in the urine of four schizophrenic patients. Br J Psychiatry 1970; 117: 421-30.
63. Cao Q, Martinez M, Zhang J, et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 1997; 43: 1-8.
64. Kaufmann CA, Suarez B, Malaspina D, et al. NIMH Genetics Initiative Millenium Schizophrenia Consortium: linkage analysis of African-American pedigrees. Am J Med Genet 1998; 81: 282-9.
65. Levinson DF, Holmans P, Straub RE, et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and l3q: schizophrenia linkage collaborative group III. Am J Hum Genet 2000; 67: 652-63.
66. Lindholm E, Ekholm B, Shaw S, et al. A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am J Hum Genet 2001; 69: 96-105.
67. Lewis CM, Levinson DF, Wise LH, et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am J Hum Genet 2003; 73: 34-48.
68. Bly M. Examination of the trace amine-associated receptor 2 (TAAR2). Schizophr Res 2005; 80: 367-8.
69. Duan J, Martinez M, Sanders AR, et al. Polymorphisms in the trace amine receptor 4 (TRAR4) gene on chromosome 6q23.2 are associated with susceptibility to schizophrenia. Am J Hum Genet 2004; 75: 624-38.
70. Ikeda M, Iwata N, Suzuki T, et al. No association of haplotype-tagging SNPs in TRAR4 with schizophrenia in Japanese patients. Schizophr Res 2005; 78: 127-30.
71. Duan S, Du J, Xu Y, et al. Failure to find association between TRAR4 and schizophrenia in the Chinese Han population. J Neural Transin 2006; 113: 381-5.
72. Amann D, Avidan N, Kanyas K, et al. The trace amine receptor 4 gene is not associated with schizophrenia in a sample linked to chromosome 6q23. Mol Psychiatry 2006; 11: 119-21.
73. Li T, Ball D, Zhao J, et al. Family-based linkage disequilibrium mapping using SNP marker haplotypes: application to a potential locus for schizophrenia at chromosome 22ql1. Mol Psychiatry 2000; 5: 77-84.
74. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Va1108/ 158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917-22.
75. Shifman S, Bronstein M, Sternfeld M, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296-302.
76. Shifman S, Levit A, Chen ML, et al. A complete genetic association scan of the 22q11 deletion region and functional evidence reveal an association between DGCR2 and schizophrenia. Hum Genet 2006; 120: 160-70.
77. Palmatier MA, Pakstis AJ, Speed W, et al. COMT haplotypes suggest P2 promoter region relevance for schizophrenia. Mol Psychiatry 2004; 9: 859-70.
78. Kim K-A, von Zastrow M. Old drugs learn new tricks: insights from mammalian trace amine receptors. Mol Pharmacol. 2001; 60: 1165-7.
79. O'Malley KL, Harmon S, Moffat M, Uhland-Smith A, Wong S. The human aromatic L-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. J Neurochem 1995; 65: 2409-16.
80. Borglum AD, Hampson M, Kjeldsen TE, et al. Dopa decarboxylase genotypes may influence age at onset of schizophrenia. Mol Psychiatry 2001; 6: 712-7.
81. Zhang B, Jia Y, Yuan Y, et al. No association between polymorphisms in the DDC gene and paranoid schizophrenia in a northern Chinese population. Psychiatr Genet 2004; 14: 161-3.
82. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-4.
83. Lindstrom LH, Gefvert O, Hagberg G, et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol Psychiatry 1999; 46: 681-8.
84. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am J Med Genet B Neuropsychiatr Genet 2003; 116: 103-25.
85. Laakso A, Pobjalainen T, Bergman J, et al The Al allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. Pharmacogenet Genomics 2005; 15: 387-91.
86. David JC, Coulon JF, Cavoy A, Delacour J. Effects of aging on p- and m-octopamine, catecholamines, and their metabolizing enzymes in the rat. J Neurochem 1989; 53: 149-54.
87. Brus R. Activity of some enzymes which synthesize and metabolize catecholamines in the brain and peripheral organs in developing rats. Arch Immunol Ther Exp (Warsz) 1975; 23: 449-57.
88. Grimsby J, Toth M, Chen K, et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 1997; 17: 206-10.
89. Holschneider DP, Chen K, Seif I, Shih JC. Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res Bull 2001; 56: 453-62.
90. Lenders JW, Eisenhofer G, Abeling NG, et al. Specific genetic deficiencies of the A and B isoenzymes of monoamine oxidase are characterized by distinct neurochemical and clinical phenotypes. J Clin Invest 1996; 97: 1010-9.
91. Zhu MY, Juorio AV, Paterson IA, Boulton AA. Regulation of striatal aromatic L-amino acid decarboxylase: effects of blockade or activation of dopamine receptors. Eur J Pharmacol 1993; 238: 157-64.
92. Hadjiconstantinou M, Wemlinger TA, Sylvia CP, Hubble JP, Neff NH. Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors. J Neurochem 1993; 60: 2175-80.
93. Buckland PR, O'Donovan MC, McGuffin P. Changes in dopa decarboxylase mRNA but not tyrosine hydroxylase mRNA levels in rat brain following antipsychotic treatment. Psychopharmacology 1992; 108: 98-102.
94. Buckland PR, Spurlock G, McGuffin P. Amphetamine and vigabatrin down regulate aromatic L-amino acid decarboxylase mRNA levels. Brain Res Mol Brain Res 1996; 35: 69-76.
95. Ikemoto K, Nishimura A, Oda T, Nagatsu I, Nishi K. Number of striatal D-neurons is reduced in autopsy brains of schizophrenics. Leg Med (Tokyo) 2003; 5 (Suppl 1): S221-4.
96. Jaeger CB, Teitelman G, Joh TH, et al. Some neurons of the rat central nervous system contain aromatic-L-amino-acid decarboxylase but not monoamines. Science 1983; 219: 1233-5.
97. Nagatsu I, Sakai M, Yoshida M, Nagatsu T. Aromatic L-amino acid decarboxylase-immunoreactive neurons in and around the cerebrospinal fluid-contacting neurons of the central canal do not contain dopamine or serotonin in the mouse and rat spinal cord. Brain Res 1988; 475: 91-102.
98. Jaeger CB, Ruggiero DA, Albert VR, Joh TH, Reis DJ. Immunocytochemical localization of aromatic L-amino acid decarboxylase. In: Bjorklund A, Hokfelt T, Ed, Handbook of Chemical Neuroanatomy Vol. 2. Classical transmitters in the CNS. Amsterdam, Elsevier. 1984; 387-408.
99. Ikemoto K. Significance of human striatal D-neurons: implications in neuropsychiatric functions. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 429-34.
100. 9 - tetrahydrocannabinol-induced stimulation. Nature 1974; 248: 144-5.
101. Turner D. A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother 2006; 6: 455-68.
102. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006; e-pub August 2: doi:10.1124/jpet.106.106583 Accessed August 10, 2006.
103. Baker GB, Bornstein RA, Rouget AC, et al. Phenylethylaminergic mechanisms in attention-deficit disorder. Biol Psychiatry 1991; 29: 15-22.
104. Zametkin AJ, Karoum F, Rapoport JL, Brown GL, Wyatt RJ. Phenylethylamine excretion in attention deficit disorder. J Am Acad Child Psychiatry 1984; 23: 310-4.
105. Kusaga A, Yamashita Y, Koeda T, et al. Increased urine phenylethylamine after methylphenidate treatment in children with ADHD. Ann Neurol 2002; 52: 372-4.
106. Zametkin AJ, Karoum F, Rapoport JL. Treatment of hyperactive children with D-phenylalanine. Am J Psychiatry 1987; 144: 792-4.
107. Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM. DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 1998; 18: 5901-7.
108. Ernst M, Zametkin AJ, Matochik JA, et al. High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry 1999; 156: 1209-15.
109. Hawi Z, Foley D, Kirley A, et al. Dopa decarboxylase gene polymorphisms and attention deficit hyperactivity disorder (ADHD): no evidence for association in the Irish population. Mol Psychiatry 2001; 6: 420-4.
110. Bakker SC, van der Meulen EM, Buitelaar JK, et al. A whole-genome scan in 164 Dutch sib pairs with attention-deficit/hyperactivity disorder: suggestive evidence for linkage on chromosomes 7p and 15q. Am J Hum Genet 2003; 72: 1251-60.
111. 3H] β-phenylethylamine binding sites in rat brain. Eur J Pharmacol 1982; 83: 147-8.
112. Borison RL, Diamond BI. A new animal model for schizophrenia: interactions with adrenergic mechanisms. Biol Psychiatry 1978; 13: 217-25.
113. Shannon HE, Thompson WA. Behavior maintained under fixed-interval and second-order schedules by intravenous injections of endogenous noncatecholic phenylethylamines in dogs. J Pharmacol Exp Ther 1984; 228: 691-5.
114. Risner ME, Jones BE. Characteristics of beta-phenethylamine self-administration by dog. Pharmacol Biochem Behav 1977; 6: 689-96.
115. Greenshaw AJ, Sanger DJ, Blackman DE. Effects of d-amphetamine and of β-phenylethylamine on fixed interval responding maintained by self-regulated lateral hypothalamic stimulation in rats. Pharmacol Biochem Behav 1985; 23: 519-23.
116. McClung C, Hirsh J. The trace amine tyramine is essential for sensitization to cocaine in Drosophila. Curr Biol 1999; 9: 853-60.
117. Blenau W, Baumann A. Molecular and pharmacological properties of insect biogenic amine receptors: lessons from Drosophila melanogaster and Apis mellifera. Arch Insect Biochem Physiol 2001; 48: 13-38.
118. Blum K, Noble EP, Sheridan PJ, et al. Allelic association of human dopamine D2 receptor gene in alcoholism. JAMA 1990; 263: 2055-60.
119. Gelernter J, Goldman D, Risch N. The A1 allele at the D2 dopamine receptor gene and alcoholism. A reappraisal. JAMA 1993; 269: 1673-7.
120. Tiihonen J, Vilkman H, Rasanen P, et al. Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. Mol Psychiatry 1998; 3: 156-61.
121. Ma JZ, Beuten J, Payne TJ, et al. Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence. Hum Mol Genet 2005; 14: 1691-8.
122. Wang D, Ma JZ, Li MD. Mapping and verification of susceptibility loci for smoking quantity using permutation linkage analysis. Pharmacogenomics J 2005; 5: 166-72.
123. Uhl GR, Vandenbergh DJ, Rodriguez LA, Miner L, Takahashi N. Dopaminergic genes and substance abuse. Adv Pharmacol 1998; 42: 1024-32.
124. Comings DE, Ferry L, Bradshaw-Robinson S, et al. The dopamine D2 receptor (DRD2) gene: a genetic risk factor in smoking. Pharmacogenetics 1996; 6: 73-9.
125. Spitz MR, Shi H, Yang F, et al. Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 1998; 90: 358-63.
126. Bierut LJ, Rice JP, Edenberg HJ, et al. Family-based study of the association of the dopamine D2 receptor gene (DRD2) with habitual smoking. Am J Med Genet 2000; 90: 299-302.
127. Persico AM, Bird G, Gabbay FH, Uhl GR. D2 dopamine receptor gene TaqI A1 and B1 restriction fragment length polymorphisms: enhanced frequencies in psychostimulant-preferring polysubstance abusers. Biol Psychiatry 1996; 40: 776-84.
128. Lawford BR, Young RM, Noble EP, et al. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. Am J Med Genet 2000; 96: 592-8.
129. Comings DE, Comings BG, Muhleman D, et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 1991; 266: 1793-800.
130. O'Hara BF, Smith SS, Bird G, et al. Dopamine D2 receptor RFLPs, haplotypes and their association with substance use in black and Caucasian research volunteers. Hum Hered 1993; 43: 209-18.
131. Comings DE, Muhleman D, Ahn C, Gysin R, Flanagan SD. The dopamine D2 receptor gene: a genetic risk factor in substance abuse. Drug Alcohol Depend 1994; 34: 175-80.
132. Comings DE, Rosenthal RJ, Lesieur HR, et al. A study of the dopamine D2 receptor gene in pathological gambling. Pharmacogenetics 1996; 6: 223-34.
133. Beuten J, Payne TJ, Ma JZ, Li MD. Significant association of catechol-O-methyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 2006; 31: 675-84.
134. Cole SO. Brain mechanisms of amphetamine-induced anorexia, locomotion and stereotypy: a review. Neuroscience Biobehav Rev 1978; 2: 89-100.
135. Dourish CT, Boulton AA. The effects of acute and chronic administration of β-phenylethylamine on food intake and body weight in rats. Prog Neuropsychopharmacol 1981; 5: 411-4.
136. Paul SM, Hulihan-Giblin B, Skolnick P. (+)-Amphetamine binding to rat hypothalamus: relation to anorexic potency for phenylethylamines. Science 1982; 218: 487-90.
137. Blenau W, Balfanz S, Baumann A. Amtyr1: characterization of a gene from honeybee (Apis mellifera) brain encoding a functional tyramine receptor. J Neurochem 2000; 74: 900-8.
138. Sabelli HC, Mosnaim AD. Phenylethylamine hypothesis of affective behavior. Am J Psychiatry 1974; 131: 695-9.
139. Sandler M, Ruthven CR, Goodwin BL, Coppen A. Decreased cerebrospinal fluid concentration of free phenylacetic acid in depressive illness. Clin Chim Acta 1979; 93: 169-71.
140. Kawabata M, Kobayashi K, Shohmori T. Determination of phenylacetic acid in cerebrospinal fluid by gas chromatography-mass spectrometry. Acta Med Okayama 1986; 40: 271-6.
141. DeLisi LE, Murphy DL, Karoum F, et al. Phenylethylamine excretion in depression. Psychiatry Res 1984; 13: 193-201.
142. Philips SR, Boulton AA. The effect of monoamine oxidase inhibitors on some arylalkylamines in rat striatum. J Neurochem 1979; 33: 159-67.
143. Greenshaw AJ. Functional interactions of 2-phenylethylamine and of tryptamine with brain catecholamines: implications for psychotherapeutic drug action. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 431-43.
144. Sabelli HC, Giardina WJ, Mosnaim AD, Sabelli NE. A comparison of the functional roles of norepinephrine, dopamine, and phenylethylamine in the central nervous system. Acta Physiol Pol 1973; 24: 33-40.
145. Fischer E, Spatz H, Heller B, Reggiani H. Phenethylamine content of human urine and rat brain, its alterations in pathological conditions and after drug administration. Experientia 1972; 28: 307-8.
146. Dyck LE, Durden DA, Boulton AA. Formation of β-phenylethylamine from the antidepressant, β-phenylethylhydrazine. Biochem Pharmacol 1985; 34: 1925-9.
147. Baker GB, Greenshaw AJ. Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system. Cell Mol Neurobiol 1989; 9: 1-44.
148. Paetsch PR, Baker GB, Greenshaw AJ. Induction of functional down-regulation of β-adrenoceptors in rats by 2-phenylethylamine. J Pharm Sci 1993; 82: 22-4.
149. Baumeister AA, Hawkins MF, Uzelac SM. The myth of reserpine-induced depression: role in the historical development of the monoamine hypothesis. J Hist Neurosci 2003; 12: 207-20.
150. Boulton AA, Juorio AV, Philips SR, Wu PH. The effects of reserpine and 6-hydroxydopamine on the concentrations of some arylalkylamines in rat brain. Br J Pharmacol 1977; 59: 209-14.
151. Szabo A, Billett E, Turner J. Phenylethylamine, a possible link to the antidepressant effects of exercise? Br J Sports Med 2001; 35: 342-3.
152. Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm 1984; 59: 81-7.
153. Sabelli H, Fink P, Fawcett J, Tom C. Sustained antidepressant effect of PEA replacement. J Neuropsychiatry Clin Neurosci 1996; 8: 168-71.
154. Beckmann H, Strauss MA, Ludolph E. DL-phenylalanine in depressed patients: an open study. J Neural Transm 1977; 41: 123-34.
155. Sandler M, Ruthven CR, Goodwin BL, et al. Deficient production of tyramine and octopamine in cases of depression. Nature 1979; 278: 357-8.
156. Dick DM, Foroud T, Flury L, et al. Genomewide linkage analyses of bipolar disorder: a new sample of 250 pedigrees from the National Institute of Mental Health Genetics Initiative. Am J Hum Genet 2003; 73: 107-14.
157. Pato CN, Middleton FA, Gentile KL, et al. Genetic linkage of bipolar disorder to chromosome 6q22 is a consistent finding in Portuguese subpopulations and may generalize to broader populations. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 119-21.
158. Middleton FA, Pato MT, Gentile KL, et al. Genomewide linkage analysis of bipolar disorder by use of a high-density single-nucleotide-polymorphism (SNP) genotyping assay: a comparison with microsatellite marker assays and finding of significant linkage to chromosome 6q22. Am J Hum Genet 2004; 74: 886-97.
159. Borglum AD, Bruun TG, Kjeldsen TE, et al. Two novel variants in the DOPA decarboxylase gene: association with bipolar affective disorder. Mol Psychiatry 1999; 4: 545-51.
160. Borglum AD, Kirov G, Craddock N, et al. Possible parent-of-origin effect of Dopa decarboxylase in susceptibility to bipolar affective disorder. Am J Med Genet B Neuropsychiatr Genet 2003; 117: 18-22.
161. Shifman S, Bronstein M, Sternfeld M, et al. COMT: a common susceptibility gene in bipolar disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2004; 128: 61-4.
162. Hanington E. Preliminary report on tyramine in headache. Brit Med J 1967; 2: 550-551.
163. Coutts RT, Baker GB, Pasutto FM. Foodstuffs as sources of psychoactive amines and their precursors: content significance and identification. Adv Drug Res 1986; 15: 169-232.
164. Yigit M, Ersoy L. Determination of tyramine in cheese by LC-UV. J Pharm Biomed Anal 2003; 31: 1223-8.
165. Lange J, Thomas K, Wittmann C. Comparison of a capillary electrophoresis method with high-performance liquid chromatography for the determination of biogenic amines in various food samples. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 779: 229-39.
166. Baker GB, Wong JT, Coutts RT, Pasutto FM. Simultaneous extraction and quantitation of several bioactive amines in cheese and chocolate. J Chromatogr 1987; 392: 317-31.
167. Davenport AP. Peptide and trace amine orphan receptors: prospects for new therapeutic targets. Curr Opin Pharmacol 2003; 3: 127-134.
168. Maguire JJ, Barriocanal FP, Davenport AP. Are vasoconstrictor responses to tyramine in human blood vessels, in vitro, mediated by the orphan trace amine receptor, TA1. Br J Pharmacol 2002; 131: 71P.
169. D'Andrea G, Terrazzino S, Fortin D, et al. Elusive amines and primary headaches: historical background and prospectives. Neurol Sci 2003; 24 (Suppl 2): S65-S67.
170. Fioroni L, D'Andrea G, Alecci M, Cananzi A, Facchinetti F. Platelet serotonin pathway in menstrual migraine. Cephalalgia 1996; 16: 427-30.
171. Sever PS. False transmitters and migraine. Lancet 1979; 1: 333.
172. Balbi T, Fusco M, Vasapollo D, et al. The presence of trace amines in postmortem cerebrospinal fluid in humans. J Forensic Sci 2005; 50: 630-2.
173. Shimazu S, Miklya I. Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 421-7.
174. D'Andrea G, Terrazzino S, Leon A, et al. Elevated levels of circulating trace amines in primary headaches. Neurology 2004; 62: 1701-5.
175. D'Andrea G, Granella F, Leone M, et al. Abnormal platelet trace amine profiles in migraine with and without aura. Cephalalgia 2006; 26: 968-72.
176. Strong FC, 3rd. Why do some dietary migraine patients claim they get headaches from placebos? Clin Exp Allergy 2000; 30: 739-43.
177. May A, Bahra A, Buchel C, Frackowiak RS, Goadsby PJ. PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000; 55: 1328-35.
178. Leone M, Franzini A, Bussone G. Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med 2001; 345: 1428-9.
179. Aridon P, D'Andrea G, Rigamonti A, et al. Elusive amines and cluster headache: mutational analysis of trace amine receptor cluster on chromosome 6q23. Neurol Sci 2004; 25 (Suppl 3): S279-80.
180. Johnson MP, Griffiths LR. A genetic analysis of serotonergic biosynthetic and metabolic enzymes in migraine using a DNA pooling approach. J Hum Genet 2005; 50: 607-10.
181. D'Andrea G, Perini F, Terrazzino S, Nordera GP. Contributions of biochemistry to the pathogenesis of primary headaches. Neurol Sci 2004; 25 (Suppl 3): S89-92.
182. Paulos MA, Tessel RE. Excretion of β-phenethylamine is elevated in humans after profound stress. Science 1982; 215: 1127-9.
183. Lapin IP. Beta-phenylethylamine (PEA): an endogenous anxiogen? Three series of experimental data. Biol Psychiatry 1990; 28: 997-1003.
184. Braestrup C, Nielsen M. GABA reduces binding of 3H-methyl beta-carboline-3-carboxylate to brain benzodiazepine receptors. Nature 1981; 294: 472-4.
185. Oakley NR, Jones BJ. Differential pharmacological effects of beta-carboline-3-carboxylic acid esters. Neuropharmacology 1982; 21: 587-9.
186. File SE, Baldwin HA. Effects of beta-carbolines in animal models of anxiety. Brain Res Bull 1987; 19: 293-9.
187. Glasgow JF, Middleton B. Reye syndrome - insights on causation and prognosis. Arch Dis Child 2001; 85: 351-3.
188. van Bever HP, Quek SC, Lim T. Aspirin, Reye syndrome, Kawasaki disease, and allergies; a reconsideration of the links. Arch Dis Child 2004; 89: 1178.
189. Manghani KK, Lunzer MR, Billing BH, Sherlock S. Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet 1975; 2: 943-6.
190. Fischer JE, Baldessarini RJ. False neurotransmitters and hepatic failure. Lancet 1971; 2: 75-80.
191. Lloyd KG, Davidson L, Price K, McClung HJ, Gall DG. Catecholamine and octopamine concentrations in brains of patients with Reye syndrome. Neurology 1977; 27: 985-8.
192. Faraj BA, Caplan DB, Malveaux EJ, Camp VM, Ali FM. Similarity between tyramine-induced neurotoxicity and the coma of Reye's syndrome. J Pharmacol Exp Ther 1983; 226: 608-15.
193. Faraj BA, Newman SL, Caplan DB, et al. Evidence for hypertyraminemia in Reye's syndrome. Pediatrics 1979; 64: 76-80.
194. Dourish CT, Cooper SJ. Pharmacology of β-phenylethylamine-induced seizures in mice. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 787-90.
195. 3H]-Flunitrazepam binding in the presence of phenylethylamine and its metabolites. Pharmacol Biochem Behav 1985; 23: 965-7.
196. Braestrup C, Schmiechen R, Neef G, Nielsen M, Petersen EN. Interaction of convulsive ligands with benzodiazepine receptors. Science 1982; 216: 1241-3.
197. Dyck LE, Yang CR, Boulton AA. The biosynthesis of p-tyramine, m-tyramine, and β-phenylethylamine by rat striatal slices. J Neurosci Res 1983; 10: 211-20.